🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 129 (from laksa065)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa129.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://pubmed.ncbi.nlm.nih.gov/37526048/\')), getAhrefsUnparsedNoserviceFromURL(\'https://pubmed.ncbi.nlm.nih.gov/37526048/\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/","crawl_time":1756411575,"first_indexed_time":0,"http_code":200,"src_unparsed":"gov,nih!nlm,ncbi,pubmed,\/37526048\/ s443","src_root_hash":"7295144728021232729","history_drop_reason":null,"meta_title":"Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2","meta_descriptions":["Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complem …"],"attrs_boilerpipe_text":"\n          Background and purpose:\n         \n      \n      The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), rapidly spread across the globe. Tremendous efforts have been mobilized to create effective antiviral treatment options to reduce the burden of the disease. This article summarizes the available knowledge about the antiviral drugs against SARS-CoV-2 from a neurologist's perspective.\n     \n          Methods:\n         \n      \n      We summarize neurological aspects of antiviral compounds against SARS-CoV-2 with full, conditional, or previous marketing authorization by the European Medicines Agency (EMA).\n     \n          Results:\n         \n      \n      Nirmatrelvir\/ritonavir targets the SARS-CoV-2 3c-like protease using combinatorial chemistry. Nirmatrelvir\/ritonavir levels are affected by medications metabolized by or inducing CYP3A4, including those used in neurological diseases. Dysgeusia with a bitter or metallic taste is a common side effect of nirmatrelvir\/ritonavir. Molnupiravir is a nucleotide analog developed to inhibit the replication of viruses. No clinically significant interactions with other drugs have been identified, and no specific considerations for people with neurological comorbidity are required. In the meantime, inconsistent results from clinical trials regarding efficacy have led to the withdrawal of marketing authorization by the EMA. Remdesivir is a viral RNA polymerase inhibitor and interferes with the production of viral RNA. The most common side effect in patients with COVID-19 is nausea. Remdesivir is a substrate for CYP3A4.\n     \n          Conclusions:\n         \n      \n      Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complement the current knowledge.\n    ","attrs_markdown":"# Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2\nEur J Neurol. 2023 Dec;30(12):3904-3912.   doi: 10.1111\/ene.16017.   Epub 2023 Aug 13.\n\n### Authors\n[Tamar Akhvlediani](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Akhvlediani+T&cauthor_id=37526048)  [1](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-1 \"Neolab Clinic, Tbilisi, Georgia.\") , [Raphael Bernard-Valnet](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Bernard-Valnet+R&cauthor_id=37526048)  [2](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-2 \"Neurology Service, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois), University of Lausanne, Lausanne, Switzerland.\") , [Sara P Dias](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Dias+SP&cauthor_id=37526048)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-3 \"Department of Neurology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.\") , [Randi Eikeland](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Eikeland+R&cauthor_id=37526048)  [4](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-4 \"Department of Health and Nursing Sciences, University of Agder, Grimstad, Norway.\")   [5](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-5 \"Norwegian National Advisory Unit on Tick-Borne Diseases, Sørlandet Hospital Trust, Kristiansand, Norway.\") , [Bettina Pfausler](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Pfausler+B&cauthor_id=37526048)  [6](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-6 \"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.\") , [Johann Sellner](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sellner+J&cauthor_id=37526048)  [7](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/#affiliation-7 \"Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.\") ; [Infectious Disease Panel of the European Academy of Neurology](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Infectious+Disease+Panel+of+the+European+Academy+of+Neurology%5BCorporate+Author%5D)\n\n### Affiliations\n- 1 Neolab Clinic, Tbilisi, Georgia.\n- 2 Neurology Service, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois), University of Lausanne, Lausanne, Switzerland.\n- 3 Department of Neurology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.\n- 4 Department of Health and Nursing Sciences, University of Agder, Grimstad, Norway.\n- 5 Norwegian National Advisory Unit on Tick-Borne Diseases, Sørlandet Hospital Trust, Kristiansand, Norway.\n- 6 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.\n- 7 Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.\n\n- PMID:   [37526048](https:\/\/pubmed.ncbi.nlm.nih.gov\/37526048\/)\n- DOI:   [10\\.1111\/ene.16017](https:\/\/doi.org\/10.1111\/ene.16017)\n\n## Abstract\n**Background and purpose:**  The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), rapidly spread across the globe. Tremendous efforts have been mobilized to create effective antiviral treatment options to reduce the burden of the disease. This article summarizes the available knowledge about the antiviral drugs against SARS-CoV-2 from a neurologist's perspective.\n\n**Methods:**  We summarize neurological aspects of antiviral compounds against SARS-CoV-2 with full, conditional, or previous marketing authorization by the European Medicines Agency (EMA).\n\n**Results:**  Nirmatrelvir\/ritonavir targets the SARS-CoV-2 3c-like protease using combinatorial chemistry. Nirmatrelvir\/ritonavir levels are affected by medications metabolized by or inducing CYP3A4, including those used in neurological diseases. Dysgeusia with a bitter or metallic taste is a common side effect of nirmatrelvir\/ritonavir. Molnupiravir is a nucleotide analog developed to inhibit the replication of viruses. No clinically significant interactions with other drugs have been identified, and no specific considerations for people with neurological comorbidity are required. In the meantime, inconsistent results from clinical trials regarding efficacy have led to the withdrawal of marketing authorization by the EMA. Remdesivir is a viral RNA polymerase inhibitor and interferes with the production of viral RNA. The most common side effect in patients with COVID-19 is nausea. Remdesivir is a substrate for CYP3A4.\n\n**Conclusions:**  Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complement the current knowledge.\n\n**Keywords:**  COVID-19; SARS-CoV-2; adverse outcome; antiviral therapy; comorbidity; drug-to-drug interaction; neurology.\n\n© 2023 European Academy of Neurology.\n\n## Publication types\n- Review\n\n## MeSH terms\n- Antiviral Agents \/ adverse effects\n- COVID-19\\*\n- Cytochrome P-450 CYP3A\n- Drug Interactions\n- Humans\n- Pandemics\n- Ritonavir \/ adverse effects\n- SARS-CoV-2\\*\n\n## Substances\n- Ritonavir\n- nirmatrelvir\n- Cytochrome P-450 CYP3A\n- Antiviral Agents","attrs_readable_markdown":null,"meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

🚫

NOT INDEXABLE

✅

CRAWLED

7 months ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	FAIL	`download_stamp > now() - 6 MONTH`	7.5 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://pubmed.ncbi.nlm.nih.gov/37526048/
Last Crawled	2025-08-28 20:06:15 (7 months ago)
First Indexed	not set
HTTP Status Code	200
Meta Title	Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2
Meta Description	Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complem …
Meta Canonical	null
Boilerpipe Text	Background and purpose: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), rapidly spread across the globe. Tremendous efforts have been mobilized to create effective antiviral treatment options to reduce the burden of the disease. This article summarizes the available knowledge about the antiviral drugs against SARS-CoV-2 from a neurologist's perspective. Methods: We summarize neurological aspects of antiviral compounds against SARS-CoV-2 with full, conditional, or previous marketing authorization by the European Medicines Agency (EMA). Results: Nirmatrelvir/ritonavir targets the SARS-CoV-2 3c-like protease using combinatorial chemistry. Nirmatrelvir/ritonavir levels are affected by medications metabolized by or inducing CYP3A4, including those used in neurological diseases. Dysgeusia with a bitter or metallic taste is a common side effect of nirmatrelvir/ritonavir. Molnupiravir is a nucleotide analog developed to inhibit the replication of viruses. No clinically significant interactions with other drugs have been identified, and no specific considerations for people with neurological comorbidity are required. In the meantime, inconsistent results from clinical trials regarding efficacy have led to the withdrawal of marketing authorization by the EMA. Remdesivir is a viral RNA polymerase inhibitor and interferes with the production of viral RNA. The most common side effect in patients with COVID-19 is nausea. Remdesivir is a substrate for CYP3A4. Conclusions: Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complement the current knowledge.
Markdown	# Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2 Eur J Neurol. 2023 Dec;30(12):3904-3912. doi: 10.1111/ene.16017. Epub 2023 Aug 13. ### Authors [Tamar Akhvlediani](https://pubmed.ncbi.nlm.nih.gov/?term=Akhvlediani+T&cauthor_id=37526048) [1](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-1 "Neolab Clinic, Tbilisi, Georgia.") , [Raphael Bernard-Valnet](https://pubmed.ncbi.nlm.nih.gov/?term=Bernard-Valnet+R&cauthor_id=37526048) [2](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-2 "Neurology Service, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois), University of Lausanne, Lausanne, Switzerland.") , [Sara P Dias](https://pubmed.ncbi.nlm.nih.gov/?term=Dias+SP&cauthor_id=37526048) [3](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-3 "Department of Neurology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.") , [Randi Eikeland](https://pubmed.ncbi.nlm.nih.gov/?term=Eikeland+R&cauthor_id=37526048) [4](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-4 "Department of Health and Nursing Sciences, University of Agder, Grimstad, Norway.") [5](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-5 "Norwegian National Advisory Unit on Tick-Borne Diseases, Sørlandet Hospital Trust, Kristiansand, Norway.") , [Bettina Pfausler](https://pubmed.ncbi.nlm.nih.gov/?term=Pfausler+B&cauthor_id=37526048) [6](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-6 "Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.") , [Johann Sellner](https://pubmed.ncbi.nlm.nih.gov/?term=Sellner+J&cauthor_id=37526048) [7](https://pubmed.ncbi.nlm.nih.gov/37526048/#affiliation-7 "Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.") ; [Infectious Disease Panel of the European Academy of Neurology](https://pubmed.ncbi.nlm.nih.gov/?term=Infectious+Disease+Panel+of+the+European+Academy+of+Neurology%5BCorporate+Author%5D) ### Affiliations - 1 Neolab Clinic, Tbilisi, Georgia. - 2 Neurology Service, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois), University of Lausanne, Lausanne, Switzerland. - 3 Department of Neurology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. - 4 Department of Health and Nursing Sciences, University of Agder, Grimstad, Norway. - 5 Norwegian National Advisory Unit on Tick-Borne Diseases, Sørlandet Hospital Trust, Kristiansand, Norway. - 6 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. - 7 Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria. - PMID: [37526048](https://pubmed.ncbi.nlm.nih.gov/37526048/) - DOI: [10\.1111/ene.16017](https://doi.org/10.1111/ene.16017) ## Abstract Background and purpose: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), rapidly spread across the globe. Tremendous efforts have been mobilized to create effective antiviral treatment options to reduce the burden of the disease. This article summarizes the available knowledge about the antiviral drugs against SARS-CoV-2 from a neurologist's perspective. Methods: We summarize neurological aspects of antiviral compounds against SARS-CoV-2 with full, conditional, or previous marketing authorization by the European Medicines Agency (EMA). Results: Nirmatrelvir/ritonavir targets the SARS-CoV-2 3c-like protease using combinatorial chemistry. Nirmatrelvir/ritonavir levels are affected by medications metabolized by or inducing CYP3A4, including those used in neurological diseases. Dysgeusia with a bitter or metallic taste is a common side effect of nirmatrelvir/ritonavir. Molnupiravir is a nucleotide analog developed to inhibit the replication of viruses. No clinically significant interactions with other drugs have been identified, and no specific considerations for people with neurological comorbidity are required. In the meantime, inconsistent results from clinical trials regarding efficacy have led to the withdrawal of marketing authorization by the EMA. Remdesivir is a viral RNA polymerase inhibitor and interferes with the production of viral RNA. The most common side effect in patients with COVID-19 is nausea. Remdesivir is a substrate for CYP3A4. Conclusions: Neurological side effects and drug interactions must be considered for antiviral compounds against SARS-CoV-2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complement the current knowledge. Keywords: COVID-19; SARS-CoV-2; adverse outcome; antiviral therapy; comorbidity; drug-to-drug interaction; neurology. © 2023 European Academy of Neurology. ## Publication types - Review ## MeSH terms - Antiviral Agents / adverse effects - COVID-19\* - Cytochrome P-450 CYP3A - Drug Interactions - Humans - Pandemics - Ritonavir / adverse effects - SARS-CoV-2\* ## Substances - Ritonavir - nirmatrelvir - Cytochrome P-450 CYP3A - Antiviral Agents
Readable Markdown	null
Shard	129 (laksa)
Root Hash	7295144728021232729
Unparsed URL	gov,nih!nlm,ncbi,pubmed,/37526048/ s443